# Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

> **NCT05274269** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 307 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA
- **OTHER:** Placebo (matched to ELX/TEZ/IVA)
- **OTHER:** Placebo (matched to IVA)

## Key facts

- **NCT ID:** NCT05274269
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-07-05
- **Final completion:** 2023-07-05
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274269, "Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05274269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*